The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background: 141W94 (VX-478) is a new HIV-1 protease inhibitor synthesized by Vertex Pharmaceuticals, Inc. and licensed for development by Glaxo Wellcome, Inc. and Kissei Pharmaceuticals. 141W94 is a potent and effective inhibitor of HIV protease in vitro with mean IC 50 values of 0.080 μM in infected PBL's. In a previous study, 141W94 was well tolerated by HIV-infected volunteers following...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.